On October 13, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that the United States Patent and Trademark Office (USPTO) has issued Patent No. 12,760,104 entitled, "Anti-VISTA Antibodies and Uses Thereof."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new patent claims provide coverage for TBS-2025, TuHURA’s VISTA inhibiting antibody, as well as antigen-binding fragments, modifications to the frameworks and Fc regions of the antibody, and bi-specific/multi-specific antibodies across all classes of human antibodies. Additionally, the patent provides coverage for use as a single agent or in combination with radiotherapy, chemotherapy, targeted therapies, tyrosine kinase inhibitor therapies, and immune checkpoint inhibitors, including PD-1 inhibitors. The new patent claims also provide coverage for methods of treatment that extend beyond cancer, expanding into new treatment areas like autoimmune disease and infection. The patent term extends to February 18, 2042, prior to any potential patent term adjustment and/or regulatory patent term extension.

"VISTA is increasingly becoming a critical target for intervention not only in AML and MDS but also in multiple myeloma where emerging scientific data links VISTA to treatment failure and importantly to myeloma related bone destruction," said Dr. James Bianco, President and Chief Executive Officer of TuHURA. "Having patent protection for TBS-2025 across a wide array of new molecular modifications allows us to expand our approaches to blood related cancers and widen potential therapeutic applications, including into autoimmune diseases and infection. This is of extraordinary value in not only protecting our VISTA franchise, but also in making TBS-2025 even more valuable to potential future corporate collaborators."

(Press release, TuHURA Biosciences, OCT 13, 2026, View Source [SID1234673361])

On October 13, 2026 Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") reported a multi-target strategic collaboration with Zealand Pharma A/S (NASDAQ:ZEAL), a biotechnology company transforming the future of metabolic health. Under the collaboration, the companies intend to design and develop multispecific protein therapeutics for obesity and other metabolic diseases using The Generate Platform, which integrates generative AI with high-throughput experimental validation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration is intended to accelerate the design and development of protein therapeutics for obesity and metabolic disease by combining Zealand Pharma’s expertise in metabolic health with Generate’s ability to engineer proteins with AI and refine those designs using experimental data toward the desired biological function.

"We are thrilled to collaborate with Generate, a leader in AI and structure-enabled drug generation. This collaboration expands our toolbox to include proteins, complementing our existing small-molecule and peptide capabilities and opening new approaches for polypharmacology for innovative therapeutics," said Utpal Singh, chief scientific officer at Zealand Pharma. "This collaboration reflects our strategy of expanding our platform and integrating our metabolic expertise in Copenhagen with the multi-modality expertise in Cambridge to develop next-generation therapeutics for metabolic health."

"We are excited to bring together Zealand Pharma’s deep expertise in peptide therapeutics and metabolic disease with Generate’s cutting-edge computational platform and experimental capabilities to address the continued unmet medical needs of patients with cardiometabolic disease," said Mike Nally, chief executive officer of Generate. "Together, our teams will first define what a great medicine for patients looks like for each of the two initial programs, and then leverage The Generate Platform to design multispecific candidates that meet or exceed that profile."

About the Collaboration

Under the terms of the agreement, Generate will use its proprietary generative AI platform to lead research through lead-candidate selection. Zealand Pharma will assume responsibility for subsequent clinical development, regulatory submissions, and worldwide commercialization.

For the two initial programs, Generate will receive $30 million upfront and up to $35 million in early preclinical milestones, and is eligible for total milestones of nearly $1.2 billion, including potential development, regulatory, and commercial milestones, plus tiered royalties on future worldwide net sales of any commercialized products resulting from the collaboration.

Ropes & Gray LLP acted as legal advisor to Generate, and Cooley LLP acted as legal advisor to Zealand Pharma.

(Press release, Generate Biomedicines, OCT 13, 2026, View Source;docid=7c037a5bbc2a99ff3971c534ee33d89ad1b256d1&content=prnews&format=html [SID1234673360])

On October 13, 2026 Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") reported that it has elevated Dr. Kulbir Singh to be the Company’s Chief Technology Officer. The Company also announces its annual stock option grant, consisting of the grant of 2,375,000 incentive stock options under the Company’s Stock Option Plan ("Option Plan"), of which 2,070,000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.35 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company’s Option Plan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sona CEO David Regan commented, "Dr. Singh’s appointment as Chief Technology Officer recognizes his leadership in advancing Sona’s THT delivery system and the critical role he plays in moving our technology toward commercialization. As a co-founder of the Company and co-inventor of Sona’s core patented technology, he brings deep technical expertise and a longstanding commitment to Sona. His work is particularly important as we optimize the delivery system for Sona’s THT cancer therapy in preparation for the next phase of our clinical program. We look forward to providing the market with an update on that program soon."

"The annual stock option grant aligns our team with shareholders and rewards the sustained effort required to advance Sona’s technology. Stock options remain the sole compensation provided to our directors, preserving cash to be used to advance our clinical progress."

(Press release, Sona Nanotech, OCT 13, 2026, View Source [SID1234673359])

On October 13, 2026 Sibylla Biotech reported key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership. Co-founder and previous CEO Lidia Pieri, PhD, MBA, will remain with the company in the role of Chief Operating Officer. Sibylla also announced the promotion of Elena Ardini, MSc, from Vice President, Research and Development to Chief Scientific Officer. The executive leadership team expansion highlights the company’s progress in validating its differentiated folding interference protein degradation technology and its commitment to bringing its lead program into clinical evaluation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Sibylla has evolved as an organization, making this the right time to expand the executive team and drive further momentum. Usman brings a powerful combination of company building and oncology research and development experience to lead Sibylla toward first-in-human studies. This progress would not have been possible without the strong foundation Lidia built as founding CEO, and we highly value her continued leadership as we enter this new chapter. The Board and I are convinced that the team is well positioned to accelerate the development of Sibylla’s highly differentiated protein degradation approach and emerging oncology pipeline," said Dieter Weinand, Chairman of the Board of Sibylla Biotech.

"By pursuing protein folding interference, Sibylla has the potential to expand the druggable proteome, unlocking therapeutic protein targets that have historically presented significant development challenges. Early intervention and disruption of the protein folding process represents an entirely new mechanism and class of degraders that could change the oncology treatment paradigm," added Dr. Azam. "Together with our world-class executive team, Sibylla is focused on advancing its lead program targeting Cyclin D1 into the clinic and validating the therapeutic potential of this novel protein degradation approach."

With nearly three decades of experience at global pharmaceutical companies and pioneering biotechs, Dr. Azam most recently served as Chief Executive Officer of CUE Biopharma, where he led the company’s strategic repositioning toward autoimmune diseases. His prior CEO roles include Inspirna, Inc., a privately held clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs, and Empyrean Neuroscience, a genetic engineering company. Before that, he served as President and CEO of Tmunity Therapeutics, a biotech developing genetically engineered CAR-T cell therapies for solid tumors. He held various senior research and development roles at Novartis, including serving as Global Head of the Cell and Gene Therapies Unit, where he helped deliver and launch the first-ever FDA approval for a CAR-T cell therapy in hematologic cancers. Earlier in his career, Dr. Azam also held senior research and development and executive roles at Aspreva Pharmaceuticals, Johnson & Johnson, GSK and Pfizer. He received his Bachelor of Medicine and Surgery and a BS in Anatomy and Human Biology from the University of Liverpool.

Before joining Sibylla as CFO, Mr. Fuggetta was Senior Vice President of Finance and Principal Financial Officer of Gain Therapeutics (NASDAQ: GANX), a clinical-stage biotechnology company. As a member of the executive leadership team, he partnered with the CEO on capital allocation and pipeline strategy, supported the company’s public equity financings and investor relations, and built the long-range financial planning. Earlier in his career, Mr. Fuggetta spent nine years at PwC in Milan, New York, and Munich, advising SEC-registered multinationals on financial reporting, M&A, and complex transactions under US GAAP and IFRS. He holds a BS in Economics from Università Cattolica, an MSc in Accounting from Università Bocconi, and an MBA from Politecnico di Milano.

Mrs. Ardini is an accomplished oncology research and development leader with more than 25 years of experience driving the discovery and development of innovative cancer therapeutics. Before her position as Vice President, Research and Development at Sibylla, she held various senior research and development roles at Nerviano Medical Sciences, including Project Leader for entrectinib (Rozlytrek), a globally approved targeted cancer therapy, and she was the principal scientific driver of non-clinical development and early clinical strategy. Earlier in her career, she held research scientist roles at New York University Medical Center and Istituto Nazionale dei Tumori di Milano. She received a MSc in Biological Sciences from the University of Milano.

(Press release, Sibylla Biotech, OCT 13, 2026, View Source [SID1234673358])

On October 13, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL siRNA gene-silencing platform, reported the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next stage of clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The batch was manufactured in accordance with established specifications and quality requirements, as confirmed by the accompanying Certificate of Analysis and Certificate of Compliance. Manufacturing was conducted in compliance with current Good Manufacturing Practice (cGMP) regulations, the approved Master Batch Record, and applicable ICH Q7 guidelines.

Validated drug substance will now proceed through the final steps of drug product completion for use in Phio’s planned Phase 2b clinical study, which is expected to be initiated in the first quarter of 2027. Successful completion of this commercial-scale manufacturing milestone underscores the Company’s supply chain readiness and supports the next steps in its clinical development and potential commercialization strategy for PH-762.

"This achievement culminates a complex coordination and cross functional execution process started some 16 months ago among numerous highly skilled scientists and engineers," said Robert Bitterman, President and CEO of Phio Pharmaceuticals. "This is a meaningful advancement in the PH-762 program, mitigating key development and manufacturing risks, and positions the Company to execute on important upcoming clinical and regulatory milestones."

(Press release, Phio Pharmaceuticals, OCT 13, 2026, View Source [SID1234673357])